Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$112.19 USD
-1.50 (-1.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $112.16 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 481 - 500 ( 520 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials; GIST Data Ahead at ASCO Likely to Inform Regulatory Strategy. Reiterate OUTPERFORM and Increasing PT to $55.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-667 RET Study Enrollment Begins, AACR Landscape; Reiterate OUTPERFORM and Raising PT to $50
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; Expansion Cohorts on Track; Multiple Data Points in 2017, Reiterate OUTPERFORM and $43 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Early BLU-285 Data in Systemic Mastocytosis Look Favorable Relative to Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Proof of Concept for BLU-285 in GIST Reported at ENA; Reiterate OUTPERFORM and Raising PT to $43 (from $41)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Shows Benefit in Advanced HCC Patients, Including Those With FGF19 Overexpression
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Abstract Reports Early Proof of Concept for Targeting FGFR4, Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for BLU-285 in SM Patients; GIST and BLU-554 data at "Triple" Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC Data Preview Ahead of Preliminary Ph 1 Data Readouts
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D